8.19

3.65% -0.31

Ventyx Biosciences Inc (VTYX)

Overview News Price History Option Chain Financials Why VTYX Down? Discussions Forecast

Ventyx Biosciences Inc stock is traded at $8.19, with a volume of 783.04K. It is down -3.65% in the last 24 hours and down -13.88% over the past month. Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Previous Close:

$8.50

Open:

$8.51

24h Volume:

783.04K

Relative Volume:

0.20

Market Cap:

$584.43M

Revenue:

Net Income/Loss:

$-192.96M

P/E Ratio:

-2.4818

EPS:

-3.3

Net Cash Flow:

$-167.04M

1W Performance:

-6.08%

1M Performance:

-13.88%

6M Performance:

+228.92%

1Y Performance:

+235.66%

1-Day Range:

$8.055

$8.51

1-Week Range:

$8.055

$9.1293

52-Week Range:

$0.783

$10.55

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Name

Ventyx Biosciences Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

(760) 407-6511

Address

12790 EL CAMINO REAL, SUITE 200, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

VTYX's Discussions on Twitter

Compare VTYX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTYX Ventyx Biosciences Inc	8.19	606.55M	0	-192.96M	-167.04M	-3.30
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-25	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-12-24	Upgrade	Oppenheimer	Perform → Outperform
Mar-12-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-07-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-07-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-07-23	Downgrade	Oppenheimer	Outperform → Perform
Nov-07-23	Downgrade	Stifel	Buy → Hold
Nov-07-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-14-23	Resumed	Credit Suisse	Outperform
Mar-21-23	Initiated	Wells Fargo	Overweight
Dec-19-22	Initiated	Goldman	Buy
Nov-17-22	Initiated	Morgan Stanley	Overweight
Sep-07-22	Initiated	Stifel	Buy
Sep-01-22	Initiated	H.C. Wainwright	Buy
May-09-22	Initiated	Credit Suisse	Outperform
Mar-31-22	Initiated	Canaccord Genuity	Buy
Feb-01-22	Initiated	Oppenheimer	Outperform
Nov-15-21	Initiated	Jefferies	Buy
Nov-15-21	Initiated	Piper Sandler	Overweight

View All

Ventyx Biosciences Inc Stock (VTYX) Latest News

Dec 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc.VTYX - PR Newswire

Dec 11, 2025

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 11% Over the Past Week - 富途牛牛

Dec 11, 2025

Dec 10, 2025

VTYX Investor Notice: Levi & Korsinsky Investigates Ventyx Biosciences, Inc. for Securities Law Violations - ACCESS Newswire

Dec 10, 2025

Ventyx shares drop after pushing back Phase 2 interim results to early 2026 - MSN

Dec 10, 2025

Dec 06, 2025

Ventyx Biosciences (NASDAQ:VTYX) Trading 12.3% HigherHere's Why - MarketBeat

Dec 06, 2025

Affinity Asset Advisors LLC Invests $9.71 Million in Ventyx Biosciences, Inc. $VTYX - MarketBeat

Dec 06, 2025

Dec 03, 2025

Ventyx Biosciences (NASDAQ:VTYX) Shares Gap DownShould You Sell? - MarketBeat

Dec 03, 2025